Clinical trials: Vancomycin, open to volunteers
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Pharmacokinetics, Amoxicillin-clavulanate
Antibiotic Dosing in Pediatric Intensive Care
Pharmacokinetics of antibiotics in critically ill neonates, infants and children
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Vancomycin
- Trial name
- ADIC (NCT02456974)
- Testing
- blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care, blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care., blood sampling in patients receiving vancomycin as part of routine clinical care.
- Where
- Belgium
- Volunteers
- 640 people
- Sponsor
- University Hospital, Ghent
Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder
Vancomycin in Primary Sclerosing Cholangitis in Italy
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.
- Conditions
- Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD
- Trial name
- VanC-IT (NCT05876182)
- Testing
- Oral Vancomycin
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- University of Milano Bicocca
Pharmacokinetics, Amoxicillin-clavulanate
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Trial name
- PADECMO (NCT06426836)
- Testing
- Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Where
- 3 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- University Hospital, Ghent
Hydrocephalus, Ventriculoperitoneal Shunt Infection
Efficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies
Objectives Primary: To measure the reduction in VP shunt infection rates using topical vancomycin powder. Secondary: To compare efficacy across different Etiological Strata (Congenital, Post-hemorrhagic, post-inflammatory).
- Conditions
- Hydrocephalus, Ventriculoperitoneal Shunt Infection, Surgical Site Infection (SSI), Cerebrospinal Fluid Shunt Infection
- Trial name
- NCT07547826
- Testing
- Topical Vancomycin Powder, Standard Perioperative Care
- Where
- Egypt
- Volunteers
- 164 people
- Sponsor
- Assiut University
Sepsis, Sepsis Mrsa
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
- Conditions
- Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy
- Trial name
- REVAMP (NCT05975671)
- Testing
- Multifaceted de-implementation strategy to reduce vancomycin overuse
- Where
- 4 sites in United States
- Volunteers
- 52,500 people
- Sponsor
- Children's Hospital of Philadelphia
Sepsis, Infections
Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)
A challenge to intermittent vancomycin dosing in young infants is the avoidable delay caused by the need to wait until steady state (i.e.
- Conditions
- Sepsis, Infections, Bacteremia
- Trial name
- VANCAPP (NCT05770622)
- Testing
- First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)
- Where
- 4 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Murdoch Childrens Research Institute
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Sepsis
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
The goal of this clinical trial is to determine if vancomycin dosing in children with sepsis can be improved by using updated, personalized dosing models that account for new markers of an individual's kidney function.
- Trial name
- VAST-i (NCT07084129)
- Testing
- personalized dosing adjustment of vancomycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Primary Sclerosing Cholangitis, Biliary Atresia
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism.
- Trial name
- NCT02137668
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sacramento Pediatric Gastroenterology